Episurf Medical AB (“Episurf” or the “Company“) announces that the Board of Directors has resolved to withdraw the proposal for a resolution on the approval of a related-party transaction between a subsidiary and a related party from the agenda of the Extraordinary General Meeting to be held on Thursday, 12 November 2026.
The Board of Directors’ proposal for a resolution at the Extraordinary General Meeting concerned the approval of Episurf’s subsidiary Frusipe Intressenter Target 1 AB (the “Subsidiary“) accepting a contemplated tender offer from Ilija Batljan Invest AB (publ) (“IBI“) in respect of bonds issued by IBI with ISIN SE0016101810 (the “Bonds“). The Subsidiary holds Bonds with a nominal value amounting to SEK 332,500,000.
The withdrawn proposal constituted item 9 on the agenda set out in the notice convening the Extraordinary General Meeting to be held on 12 November 2026. The other proposed resolutions on the agenda remain unchanged, and the Extraordinary General Meeting will otherwise be held in accordance with the notice convening the Extraordinary General Meeting published by the Company on 12 October 2026.
– Following an overall assessment, the Board of Directors has concluded that it is more advantageous for Episurf and its shareholders not to carry out the transaction in the manner originally proposed. The Subsidiary will therefore retain the Bonds, which we consider places the Company in a better position than accepting the tender offer on the terms available. We will continue to manage the holding based on what creates the most value for the Company, says Jens Andersson, CEO of Episurf.
For further information, please contact:
Jens Andersson, CEO, Episurf Medical
Tel: +46 (0) 768 55 67 02
Email: jens.andersson@episurf.se
The information was submitted for publication, through the agency of the contact person set out above, at 13:00 CET on 30 October 2026.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation.
Episurf Medical is a property company with exposure to a diversified portfolio of property assets. The Company’s objective is to create value growth through the acquisition and management of Nordic properties. The Company also has a medical technology operation based on the individualized implant Episealer® and associated surgical instruments, which are used to treat cartilage injuries in joints. Episurf Medical’s head office is in Stockholm, Sweden.
This press release has been published in Swedish and English. In the event of any discrepancy between the language versions, the Swedish version shall prevail.